InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology
In Development

When it comes to identifying cancer, there's no such thing as too early. The GlycoKnow™ Colon test is being developed as a laboratory-developed risk assessment test that uses glycopeptide and peptide biomarkers to assess the presence of adenomas with high-grade dysplasia or colorectal cancer. Once finalized, a single blood draw should be able to put patients with an increased risk of colon cancer on the path to receiving care before a tumor has developed.

GlycoKnow Colon is intended to be complementary to—and not a replacement for—current recommended colorectal cancer testing methods.

Single-tube blood draw

Pre-cancer detection to assess the presence of adenomas with high-grade dysplasia or CRC

Rapid 10-day
turnaround time

InterVenn Biosciences' clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing, and complies with College of American Pathologists (CAP) Proficiency Testing requirements. The GlycoKnow Colon test is developed, and its performance characteristics determined, by InterVenn Biosciences. The GlycoKnow Colon test has not been cleared or approved by the U.S. Food and Drug Administration.

Product Pipeline

Indication Clinical Application Phase
Proof of Concept Classifier Validation LDT Validation Commercially Available
GLORI™ Pelvic Mass Triaging
DAWN™ IO MelanomaImmuno-Therapy Response Prediction
Non-Small Cell Lung Carcinoma (NSCLC)Immuno-Therapy Response Prediction
GlycoKnow™ ColonPre-Malignant Detection, Cancer Prevention
Multiple Cancer Early Detection: Breast, Colon, Lung, Pancreas, ProstateEarly Detection
Treatment Monitoring Panel: AutoimmuneDisease Monitoring
Treatment Monitoring Panel: InflammationDisease Monitoring
Treatment Monitoring Panel: Infectious DiseaseDisease Monitoring

Get in touch